

HIV Research @ the SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH AIDS Office



Erin Wilson, DrPH
Senior Research Scientist
Center for Public Health Research
Director, Trans Research Unit for Equity
erin.wilson@sfdph.org

Associate Professor
Department of Epidemiology and Biostatistics
UCSF
erincwilson@gmail.com

Bridge HIV

Center for
Public Health
Research

Center for
Learning and
innovation


Community Health
Equity and Promotion
(CHEP)

HIV care
services

Applied Research, Community Health
Epidemiology, and Research
(ARCHES)

SFDPH

AIDS Office



ARCHES - HIV EPIDEMIOLOGY AND CORE SURVEILLANCE SECTION

- Provide Metrics to Monitor Success of all Getting to Zero Strategic Initiatives
 - Core HIV/AIDS Surveillance
 - Molecular HIV Surveillance
 - Medical Monitoring Project



Wayne Enanoria,
PhD, MPH



Ling Hsu, MPH



HIV EPIDEMIOLOGY AND SURVEILLANCE

https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2019_Indigo_20200929_Web_fixed.pdf


Annual Report **2019**



San Francisco
Department of Public Health
Population Health Division

government mandates


- AIDS case reporting since 1981, name-based HIV case reporting since 2006
- Mandatory dual reporting by provider and laboratory of HIV test results including all viral load and CD4 test results
- Longitudinal registry
 - Follow-up chart reviews for ART, prophylaxis, OIs, substance use including drug and tobacco use
 - Current address and housing status
 - Deaths and multiple causes of death



CENTER FOR
PUBLIC
HEALTH
RESEARCH



NATIONAL HIV BEHAVIORAL SURVEILLANCE (NHBS)



National HIV
Behavioral Surveillance

- Population based studies of HIV in San Francisco

MSM

PWID

High risk
Heterosexual

Women who
engage in sex work

Trans
Women



Project M

Do you identify as a gay or bisexual cis man and live in San Francisco or San Mateo County?

Share your experiences about health and earn up to \$125.

Help create a healthy SF Bay Area!

TAKE SURVEY

This is a paid research study at the San Francisco Department of Public Health.

A promotional banner for the Project M survey. It features a vibrant rainbow graphic on the left side. The text is in a mix of white and yellow fonts against a dark purple background. A blue button with the text "TAKE SURVEY" is prominently displayed, with a white hand icon pointing at it. At the bottom, there is a small line of fine print.

HIV RESEARCH, PREVENTION AND CARE AMONG TRANS PEOPLE



TRUE RESEARCH, DOMESTIC RESEARCH & TRAINING



WELCOME



2021-2024

er
native phase)


H, ROI



wing the epidemic and
ng intersectional stigma

TRUE INTERNATIONAL RESEARCH

- BeT Intervention – Rio de Janeiro Brazil
 - UG3/UH3 Status neutral HIV systems navigation and anti-stigma intervention for young trans women in Brazil
- Sweekar Intervention – Kathmandu, Nepal
 - R2I Stigma and HIV risk study of trans women in Nepal



CENTER ON SUBSTANCE USE AND HEALTH (CPHR).

WWW.CSUHSF.ORG



Phillip Coffin



Glenn-Milo Santos



Vanessa McMahan


Observational Studies



	ODS	COPING	Stimulant OD
Population & Setting	People prescribed opioids (N= 600)	People prescribed opioids (N= 300-400)	Stimulant overdose decedents (N= 100)
Intervention	Observational	Observational	Observational
Primary outcome	HIV outcomes	Pain and function	Cause and antecedents to death
Design	Chart review	Longitudinal cohort, up to 4yr f/u	Psychological autopsies

CENTER ON SUBSTANCE USE AND HEALTH

Ongoing Randomized Intervention Trials



	REBOOT 2.0	Say When (analysis phase)	M3	PRIME
Population	People who use opioids (N=300)	Binge-drinking MSM (N=120)	Adults with meth use d/o (n=24)	MSM who inject meth (N=140)
Intervention & Control	Counseling for overdose prevention	Oral naltrexone vs. placebo, as-needed	Mirtazapine v placebo	Video DOT v Counseling
Outcome	Overdose events	Alcohol Use, Sexual Risk Behaviors	Drug interaction study with methamphetamine	PrEP adherence
Design	Single-blind RCT, 16-month f/u	Double-blind RCT, 3 month f/u	Double-blind RCT, 14 days	RCT, 6m f/u



Recently Completed/Ongoing Pharmacologic Intervention Trials

Glenn-Milo Santos, PhD



	Curb the Line (Analysis Phase)	Harness	HiNT
Population	People with cocaine Use disorders (N=45)	People with alcohol use disorders (n=120)	MSM with mild to moderate meth use disorder (n=54)
Intervention & Control	ER Lorcaserin vs. placebo	Kudzu vs. placebo, as-needed	Oral naltrexone vs. placebo, as-needed + Ecological Momentary Intervention
Outcome	Cocaine Use and Cocaine-Associated Sexual Risk Behaviors	Alcohol Use, Sexual Risk Behaviors, STIs	Meth Use and Meth-Associated Sexual Risk Behaviors, PrEP and ART adherence
Design	Double-blind RCT, 3 month f/u	Double-blind RCT, 3 month f/u	Double-blind RCT, 3 month f/u

CENTER ON SUBSTANCE



CENTE
IN ACA
ON OP

Promoting balance to opioid stewardship

We are a learning hub for innovative training and technical assistance to support clinicians in providing compassionate chronic pain and opioid management


LOCAL

S.F. on course for record-breaking number of drug overdoses in 2021



Yoohyun Jung


May 21, 2021 | Updated: May 22, 2021 4 a.m.



BRIDGE HIV: A TRADITION OF INNOVATIVE RESEARCH TO PREVENT HIV/AIDS



Susan Buchbinder, MD



Albert Liu, MD, MPH



Hyman Scott, MD, MPH

SF City Clinic Cohort Study

- HIV antibody test
- Natural history
- Long term non-progression (LTNP)

Vaccines Prep


- Recruitment and retention of at-risk cohorts
- Risk factors for infection
- Per-contact risk

Behavioral and Biomedical Interventions

- Individualized, client centered counseling
- **Preventive Vaccines**
- STD interventions (HSV-2 suppression)
- **Pre-exposure Prophylaxis**
- **Rectal and vaginal microbicides**
- **Peer navigation among Black and Latino MSM and trans people**
- **Home HIV and STI testing**

Evaluating Platforms for Intervention Delivery and Building Research Capacity

- **Combination Prevention***
- **Implementation Research**
- **Fostering a new generation of HIV researchers**
- **mHealth**




COVID-19
Prevention Network



Novel PrEP agents
Long acting PrEP formulations
Integrated Strategies


PrEP support tools

HIV Vaccines
bNAbs



COVID-19 PREVENTION NETWORK (COVPPN)

- Formed by NIH
 - Global network of NIH sites and Clinical Research Organization sites, as needed
 - Links together multiple NIH-sponsored networks
 - Local sites include Bridge HIV (SFDPH), UCSF/ZSFG, EBAC (Oakland), SFVAH
- Mission: To conduct Phase III efficacy trials to prevent infection and COVID-19 disease
- Running 5 COVID-19 vaccine efficacy trials and several COVID-19 antibody studies
- Example – AZD1222 Study in San Francisco
 - Enrolled 256 participants in the AstraZeneca trial
 - Prioritized access for Black, Latinx, Pacific Islander, and Native American study participants
 - Goal: Vaccine study participants reflect the communities most impacted by COVID-19
 - Bridge HIV Site: 32% Latinx, 20% Black/African American, 20% Asian, 19% White, 13% Asian, 2% Native Hawaiian/Pacific Islander; 1% American Indian/Alaskan Native; 30% over 60 yo



COMMUNITY ENGAGEMENT IN THE ERA OF COVID

F*CKING CORONA!

SEX. SANITY. PLEASURE.
GIVING YOU THE 411 ON 4/11.

4PM / SATURDAY
APRIL 11,
2020

JOIN US ON A **FREE ZOOM CALL**
WITH A NURSE, A SEX THERAPIST,
AND A FABULOUS DILDO DEALER:

FCKINGCORONA.EVENTBRITE.COM



RAFAEL GONZALEZ
BRIDGEHIV.ORG



NENNA JOINER
FEELMORE510.COM



MACHEL L. HUNT, MSC PSYCH.
SEXTHERAPYFORYOU.COM



ALLISON PHILLIPS, DNP, NP-C
BRIDGEHIV.ORG

BridgeHIV®

TRANS*COVID

A CONVERSATION TO ADDRESS THE TRANS COMMUNITY'S
CONCERNS & TRANSCEND BEYOND THE COVID-19 PANDEMIC.

4PM / SATURDAY
MAY 16, 2020

JOIN US ON ZOOM TO HELP EMPOWER OUR
COMMUNITY & PROMOTE SELF ADVOCACY:
TRANSCOVID.EVENTBRITE.COM



LOTUS DÓ, LCSW
HE/HIM THEY/THEM



KRISTINA JA'LYXIE BLIOUX, CPT1
SHE/HER/HERS



NENNA JOINER
FEELMORE510.COM
THEY/THEM



LAURYN TERRY, RN
SHE/HER/HERS

STAY BridgeHIV®

STUDIES UNDERWAY OR ON THE HORIZON

Pharma – funded studies for PrEP and STIs

- Merck - New monthly PrEP pill for MSM/TGW
- Gilead - New semi-annual injectable PrEP for TGW
- GlaxoSmithKline Study of genital herpes outbreaks
- Possible study of the meningococcal vaccine to prevent gonorrhea

AMBER

- Socio-behavioral research to guide PrEP implant development in MSM, cisgender women, and TGW

PrEP and ART implementation

- PCORI: Comparative effectiveness trial evaluating 2 mobile technologies to support PrEP use
- Viiv: Novel delivery model for injectable ART treatment for trans women
- HOPE: Mobile clinic delivery of HIV status neutral services to the African American community
- HPTN 091: Co-localization of PrEP and gender affirming hormone therapy for transgender women

HIV Vaccines and monoclonal antibodies

- Mosaico: HIV vaccine efficacy trial (fully enrolled)
- Four Phase I or 2 studies of new vaccine or monoclonal antibodies for HIV prevention

CENTER FOR LEARNING & INNOVATION


SHARP SUMMER HIV/AIDS RESEARCH PROGRAM



<https://sharpinternship.org/>



<https://getsfcba.org/>



PrEPmate

Evidence-Based for Retention in PrEP Care

Evidence-Based for PrEP Medication Adherence/Persistence

